Stay updated on Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page.

Latest updates to the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2. This update appears to be a metadata change with no impact on study details.SummaryDifference0.1%

- Check19 days agoChange DetectedThe general government funding status notice related to NIH operations has been removed, but this does not affect the study details, eligibility, or enrollment information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check34 days agoChange DetectedThe update appears to be limited to minor layout and formatting adjustments on the study page; core details like inclusion criteria, outcomes, and participating sites remain unchanged.SummaryDifference0.4%

- Check62 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference4%

- Check69 days agoChange DetectedUpdated to Revision: v3.1.0 with expanded contact details; old Revision: v3.0.2 removed.SummaryDifference0.1%

- Check84 days agoChange DetectedUpdated from v3.0.1 to v3.0.2; removed the 'Back to Top' element. No other substantive changes to core content, pricing, stock, or time-slot availability.SummaryDifference0.2%

Stay in the know with updates to Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib in 2nd-line Biliary AdenoCa Clinical Trial page.